List view / Grid view
A team from the University of Texas at Dallas has shown that a novel buffer solution is effective at stabilising the liposomes and lipid nanoparticles in certain COVID-19 vaccines.
Results of a recent study by researchers at the University of Bristol indicate neuropilin-1 is an important host factor for SARS-CoV-2 infection. The team suggests that blocking neuropilin-1 may be a valuable therapeutic intervention in the treatment of COVID-19. Nikki Withers spoke to one of the study’s lead investigators, Dr…
A study has discovered that a biomarker associated with pancreatitis is involved in its development to pancreatic cancer.
3 November 2015 | By Victoria White
The collaboration will leverage the scientific expertise of the two organisations to discover and develop up to five cancer immunotherapies...
26 June 2015 | By Victoria White
Siemens and BioNTech will work together on the construction of a fully automated and digitalised production site for BioNTech's personalised cancer vaccines...
11 June 2015 | By Victoria White
BioNTech has launched MammaTyper, a molecular diagnostic test for breast cancer, for universal use in pathology laboratories in Europe...
19 May 2015 | By Victoria White
BioNTech has signed an agreement with Genmab to jointly research, develop and commercialise multiple bispecific antibodies for cancer immunotherapy...
12 May 2015 | By Victoria White
BioNTech and Lilly are to collaborate to identify and validate novel tumour targets and their corresponding TCRs in one or more types of cancer...
